Skip to main content
. 2013 Aug 27;23(12):1396–1413. doi: 10.1038/cr.2013.113

Figure 7.

Figure 7

mIno80 haploinsufficiency is associated with postnatal growth defects and altered tumor spectrum in a p53-null background. (A) Body weights of mIno80F/F and CAG-CreER; mIno80F/F mice after tamoxifen (TAM) injection. Error bars represent s.e.m. and asterisks indicate statistically significant weight differences (*P < 0.05; **P < 0.005; ***P < 0.001, Student's t-test). (B) Kaplan-Meier survival analysis of mIno80F/F and CAG-CreER; mIno80F/F mice after TAM injection. The log rank test was used to compare difference in survival (P = 0.0048). (C) Quantification of tumor number and spectrum (thymic lymphomas, B-cell lymphomas in the spleen and lymph nodes as well as all other tumor types) in mIno80+/−; p53−/− mice compared to p53−/− mice. (D) Representative H&E sections of lymphomas and sarcomas in mice of the indicated genotypes. Inset: arrowheads point to pleomorphic giant nuclei. (E) Kaplan-Meier analysis for tumor-free survival of mIno80+/−; p53−/− mice compared to p53−/− mice. The log rank test (P = 0.9422) showed no significant differences in tumor-free survival between the two cohorts.